Oral GLP-1 receptor agonists: competition for efficacy and tolerability - PubMed
6 hours ago
- #diabetes treatment
- #GLP-1 receptor agonists
- #conflict of interest
- Oral GLP-1 receptor agonists are being compared for efficacy and tolerability.
- MAN has multiple conflicts of interest, including advisory roles and consulting with pharmaceutical companies like Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.
- MAN has also received support for travel and meetings from Eli Lilly and Novo Nordisk.
- MH was involved with Glyscend Therapeutics, which closed in January 2025, nullifying stock options.
- MH serves on unpaid advisory boards for Alstemi Medical and Altrix Bio, focusing on diabetes and obesity treatments.
- MH received travel support from the European Association for the Study of Diabetes.